KAI 1678

Drug Profile

KAI 1678

Alternative Names: KAI-1678

Latest Information Update: 19 Aug 2015

Price : $50

At a glance

  • Originator KAI Pharmaceuticals
  • Developer Amgen
  • Class Anti-inflammatories; Non-opioid analgesics; Peptides; Small molecules
  • Mechanism of Action Protein kinase C epsilon inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuropathic pain; Postoperative pain

Most Recent Events

  • 05 Jul 2012 KAI Pharmaceuticals has been acquired by Amgen
  • 22 Apr 2010 KAI Pharmaceuticals completes a phase IIa trial (NCT01106716) in Neuropathic pain in Australia
  • 21 Oct 2009 Pharmacodynamics data from a preclinical study in Neuropathic pain presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top